MedTrace Logo

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 308

Last updated 2026-04-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.

Conditions

  • Relapsed/Refractory Non-Hodgkin Lymphoma

Interventions

DRUG

BMS-986458

Specified dose on specified days.

DRUG

Rituximab

Specified dose on specified days.

DRUG

Glofitamab/Obinutuzumab

Specified dose on specified days

DRUG

Mosunetuzumab

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-29
Primary Completion
2027-10-28
Completion
2028-10-28
FDA Drug
Yes

Countries

  • United States
  • Chile
  • China
  • France
  • Germany
  • Greece
  • Italy
  • Japan
  • Netherlands
  • South Korea
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06090539 on ClinicalTrials.gov